CDH22 hypermethylation is an independent prognostic biomarker in breast cancer.
Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Córdoba A, Vicente-García F, Blanco-Luquin I, De La Cruz S, Aramendia A, Guerrero-Setas D.
Martín-Sánchez E, et al. Among authors: aramendia a.
Clin Epigenetics. 2017 Jan 24;9:7. doi: 10.1186/s13148-016-0309-z. eCollection 2017.
Clin Epigenetics. 2017.
PMID: 28149335
Free PMC article.